Daniel Thomas Ginat
Papers
2
Total Citations
75
H-Index
2
About
Daniel Thomas Ginat is a leading clinical researcher in head and neck oncology, with a focused expertise in human papillomavirus-positive oropharyngeal cancer (HPV+ OPC) and immunotherapy. His major contributions center on pioneering neoadjuvant immunotherapy strategies, specifically integrating nivolumab with chemotherapy to achieve tumor response before definitive locoregional treatment. Dr. Ginat is best known for his work on response-adaptive therapy, as demonstrated in the OPTIMA II trial, where he showed that risk-stratified, de-escalated locoregional therapy following nivolumab, nab-paclitaxel, and carboplatin can reduce treatment intensity without compromising outcomes. His 2024 study on neoadjuvant nivolumab plus chemotherapy with response-adaptive therapy has accumulated 45 citations, while the OPTIMA II trial has garnered 30 citations, reflecting the high impact of his work in reshaping curative paradigms for HPV+ OPC. By challenging the standard of care and exploring de-escalation, Ginat’s research offers patients the potential for fewer toxicities while maintaining excellent survival, marking him as a key figure in the evolution of precision, immunotherapy-driven head and neck cancer treatment.
Research Focus
Key Achievements
Top Papers
- 1
- 2